


The number of individual cases identified in EudraVigilance for **ELASOMERAN** is 361,485 (up to 03/12/2022)


Number of individual cases by Age Group

Age Group	Cases	%
Not Specified	16,150	4.5%
0-1 Month	111	0.0%
2 Months - 2 Years	172	0.0%
3-11 Years	177	0.0%
12-17 Years	2,418	0.7%
18-64 Years	284,285	78.6%
65-85 Years	52,025	14.4%
More than 85 Years	6,147	1.7%
<b>Total</b>	<b>361,485</b>	<b>100.0%</b>




Number of individual cases by Sex

Sex	Cases	%
Female	248,151	68.6%
Male	108,182	29.9%
Not Specified	5,152	1.4%
<b>Total</b>	<b>361,485</b>	<b>100.0%</b>




Number of individual cases by Geographic Origin (EEA/Non-EEA)

Occurrence Country EEA/Non EEA	Cases	%
European Economic Area	272,468	75.4%
Non European Economic Area	89,017	24.6%
Not Specified	0	
<b>Total</b>	<b>361,485</b>	<b>100.0%</b>



Reporter Group	Cases	%
Healthcare Professional	121,752	33.7%
Non Healthcare Professional	239,733	66.3%
Not Specified	0	
<b>Total</b>	<b>361,485</b>	<b>100.0%</b>


Number of individual cases by Reporter Group



For the interpretation of the results, please refer to the key considerations at [www.adrreports.eu](http://www.adrreports.eu)

Number of individual cases identified in EudraVigilance received over the last 12 months and overall for **ELASOMERAN** (up to 03/12/2022)




Number of Individual Cases received over time



For the interpretation of the results, please refer to the key considerations at [www.adrreports.eu](http://www.adrreports.eu)


Number of individual cases identified in EudraVigilance in EEA countries for ELASOMERAN (up to 03/12/2022)

The country is not displayed if the number of cases is less or equal to 3 for that country



For the interpretation of the results, please refer to the key considerations at [www.adrreports.eu](http://www.adrreports.eu)

Choose how you want to see the number of individual cases identified in EudraVigilance for **ELASOMERAN** (up to 03/12/2022)



For the interpretation of the results, please refer to the key considerations at [www.adrreports.eu](http://www.adrreports.eu)